Advertisement

Botulinum toxin therapy for temporomandibular joint disorders: a systematic review of randomized controlled trials

  • Y.-W. Chen
    Affiliations
    Department of Stomatology, Taipei Veterans General Hospital, Taipei, Taiwan

    School of Dentistry, National Yang-Ming University, Taipei, Taiwan

    Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

    Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital and Harvard School of Dental Medicine, Boston, MA, USA
    Search for articles by this author
  • Y.-W. Chiu
    Affiliations
    Department of Stomatology, Taipei Veterans General Hospital, Taipei, Taiwan
    Search for articles by this author
  • C.-Y. Chen
    Affiliations
    School of Dentistry, National Yang-Ming University, Taipei, Taiwan

    Department of Pediatric Dentistry, School of Dentistry, University of Maryland, Baltimore, MD, USA
    Search for articles by this author
  • S.-K. Chuang
    Correspondence
    Address: Sung-Kiang Chuang, Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital and Harvard School of Dental Medicine, 55 Fruit St, Warren 1201, Boston, MA 02114, USA.
    Affiliations
    Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital and Harvard School of Dental Medicine, Boston, MA, USA
    Search for articles by this author
Published:April 25, 2015DOI:https://doi.org/10.1016/j.ijom.2015.04.003

      Abstract

      The objective of this study was to undertake a systematic review to assess the efficacy of botulinum toxin therapy (BTX) for temporomandibular joint disorders (TMDs). A comprehensive search of major databases through PubMed, EMBASE, and Cochrane CENTRAL was conducted to locate all relevant articles published from inception to October 2014. Eligible studies were selected based on inclusion criteria and included English language, peer-reviewed publications of randomized controlled trials comparing BTX versus any alternative intervention or placebo. Quality assessment and data extraction were done according to the Cochrane risk of bias tool and recommendations. The entire systematic search and selection process was done independently by two reviewers. Five relevant study trials were identified, involving 117 participants. Two trials revealed a significant between-group difference in myofascial pain reduction, another trial that compared BTX with fascial manipulation showed equal efficacy of pain relief on TMDs, while the remaining two trials showed no significant difference between the BTX and placebo groups. Because of considerable variations in study methods and evaluation of results, a meta-analysis could not be performed. Based on this review, no consensus could be reached on the therapeutic benefits of BTX on TMDs. A more rigorous design of trials should be carried out in future studies.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Al-Jundi M.A.
        • John M.T.
        • Setz J.M.
        • Szentpetery A.
        • Kuss O.
        Meta-analysis of treatment need for temporomandibular disorders in adult nonpatients.
        J Orofac Pain. 2008; 22: 97-107
        • Buescher J.J.
        Temporomandibular joint disorders.
        Am Fam Physician. 2007; 76: 1477-1482
        • Dworkin S.F.
        • LeResche L.
        Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique.
        J Craniomandib Disord. 1992; 6: 301-355
        • Poveda Roda R.
        • Bagan J.V.
        • Diaz Fernandez J.M.
        • Hernandez Bazan S.
        • Jimenez Soriano Y.
        Review of temporomandibular joint pathology. Part I: Classification, epidemiology and risk factors.
        Med Oral Patol Oral Cir Bucal. 2007; 12: E292-E298
        • Lobbezoo F.
        • Drangsholt M.
        • Peck C.
        • Sato H.
        • Kopp S.
        • Svensson P.
        Topical review: new insights into the pathology and diagnosis of disorders of the temporomandibular joint.
        J Orofac Pain. 2004; 18: 181-191
        • Abenavoli F.M.
        • Corelli R.
        Hypothesis on a cause of temporomandibular joint disorders.
        Plast Reconstr Surg. 2003; 111: 2473-2474
        • Magnusson T.
        • Egermarki I.
        • Carlsson G.E.
        A prospective investigation over two decades on signs and symptoms of temporomandibular disorders and associated variables. A final summary.
        Acta Odontol Scand. 2005; 63: 99-109
        • Huang G.J.
        • LeResche L.
        • Critchlow C.W.
        • Martin M.D.
        • Drangsholt M.T.
        Risk factors for diagnostic subgroups of painful temporomandibular disorders (TMD).
        J Dent Res. 2002; 81: 284-288
        • Sellin L.C.
        • Thesleff S.
        Pre- and post-synaptic actions of botulinum toxin at the rat neuromuscular junction.
        J Physiol. 1981; 317: 487-495
        • Scott A.B.
        Botulinum toxin injection of eye muscles to correct strabismus.
        Trans Am Ophthalmol Soc. 1981; 79: 734-770
        • Clark G.T.
        • Stiles A.
        • Lockerman L.Z.
        • Gross S.G.
        A critical review of the use of botulinum toxin in orofacial pain disorders.
        Dent Clin North Am. 2007; 51 (ix): 245-261
        • Cheshire W.P.
        • Abashian S.W.
        • Mann J.D.
        Botulinum toxin in the treatment of myofascial pain syndrome.
        Pain. 1994; 59: 65-69
        • Lang A.M.
        Botulinum toxin therapy for myofascial pain disorders.
        Curr Pain Headache Rep. 2002; 6: 355-360
        • Guo B.L.
        • Zheng C.X.
        • Sui B.D.
        • Li Y.Q.
        • Wang Y.Y.
        • Yang Y.L.
        A closer look to botulinum neurotoxin type A-induced analgesia.
        Toxicon. 2013; 71: 134-139
        • Schwartz M.
        • Freund B.
        Treatment of temporomandibular disorders with botulinum toxin.
        Clin J Pain. 2002; 18: S198-S203
        • Song P.C.
        • Schwartz J.
        • Blitzer A.
        The emerging role of botulinum toxin in the treatment of temporomandibular disorders.
        Oral Dis. 2007; 13: 253-260
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Br Med J. 2009; 339: b2535
        • Higgins J.P.
        • Altman D.G.
        • Gotzsche P.C.
        • Juni P.
        • Moher D.
        • Oxman A.D.
        • et al.
        The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
        Br Med J. 2011; 343: 5928
        • Ernberg M.
        • Hedenberg-Magnusson B.
        • List T.
        • Svensson P.
        Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study.
        Pain. 2011; 152: 1988-1996
        • Guarda-Nardini L.
        • Stecco A.
        • Stecco C.
        • Masiero S.
        • Manfredini D.
        Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique.
        Cranio. 2012; 30: 95-102
        • Kurtoglu C.
        • Gur O.H.
        • Kurkcu M.
        • Sertdemir Y.
        • Guler-Uysal F.
        • Uysal H.
        Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement.
        J Oral Maxillofac Surg. 2008; 66: 1644-1651
        • von Lindern J.J.
        • Niederhagen B.
        • Berge S.
        • Appel T.
        Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity.
        J Oral Maxillofac Surg. 2003; 61: 774-778
        • Nixdorf D.R.
        • Heo G.
        • Major P.W.
        Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain.
        Pain. 2002; 99: 465-473
        • Freund B.
        • Schwartz M.
        The use of botulinum toxin for the treatment of temporomandibular disorder.
        Oral Health. 1998; 88: 32-37
        • Freund B.
        • Schwartz M.
        • Symington J.M.
        The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings.
        J Oral Maxillofac Surg. 1999; 57 (discussion 920–1): 916-920
        • Freund B.
        • Schwartz M.
        Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A.
        J Pain. 2003; 4: 159-165
        • Karacalar A.
        • Yilmaz N.
        • Bilgici A.
        • Bas B.
        • Akan H.
        Botulinum toxin for the treatment of temporomandibular joint disk disfigurement: clinical experience.
        J Craniofac Surg. 2005; 16: 476-481
        • Sidebottom A.J.
        • Patel A.A.
        • Amin J.
        Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study.
        Br J Oral Maxillofac Surg. 2013; 51: 199-205
        • Colhado O.C.
        • Boeing M.
        • Ortega L.B.
        Botulinum toxin in pain treatment.
        Rev Bras Anestesiol. 2009; 59: 366-381
        • Munchau A.
        • Bhatia K.P.
        Uses of botulinum toxin injection in medicine today.
        Br Med J. 2000; 320: 161-165
        • Odderson I.R.
        Hyperhidrosis treated by botulinum A exotoxin.
        Dermatol Surg. 1998; 24: 1237-1241
        • Borodic G.E.
        • Acquadro M.
        • Johnson E.A.
        Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects.
        Expert Opin Investig Drugs. 2001; 10: 1531-1544